Get regular updates to your inbox.
By shortening the time spent on treatment, Ultomiris (ravulizumab), an approved therapy for atypical hemolytic uremic syndrome (aHUS), may be more effective at reducing lost productivity costs compared with its predecessor Soliris (eculizumab), according to a new study. The study, “Quantifying the economic effects of ravulizumab…
Read more
Because viral infections can worsen atypical hemolytic uremic syndrome (aHUS), researchers recommend testing patients for infections that are common following an organ transplant. They describe the case of patient, whose aHUS symptoms recurred after undergoing a kidney transplant, in their report, “Concurrent cytomegalovirus enteritis and atypical…
C5a, a terminal product of the complement system, can, by itself, promote blood vessel dysfunction and the subsequent formation of blood clots seen in people with atypical hemolytic uremic syndrome (aHUS), a study shows. Notably, the same C5a-induced molecular mechanisms were detected among patients with severe COVID-19 and whose infection…
Paying attention to the details is critical for success, writes columnist Annie Dixon. Paperwork may not be exciting, but it’s necessary.
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
